Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists - Quiz - MDSpire

Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists

  • By

  • Yu-Cheng Chang

  • Chun-Yu Peng

  • Kuan-Yu Chi

  • Junmin Song

  • Yu Chang

  • Cho-Hung Chiang

  • Wenli Gao

  • Cho-Han Chiang

  • January 29, 2025

  • 0 min

Share

Original Source(s)

Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists

  • by Yu-Cheng Chang, Chun-Yu Peng, Kuan-Yu Chi, Junmin Song, Yu Chang, Cho-Hung Chiang, Wenli Gao, Cho-Han Chiang

  • January 29, 2025

Related Content

Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors

Analysis of factors associated with cognitive impairment in elderly patients hospitalized with chronic heart failure

IPS Could Minimize GI Effects in Treating Iron Deficiency

Review summarizes pharmacokinetic and clinical data on iron protein succinylate across patients with iron deficiency and iron deficiency anemia.